LB Pharmaceuticals Inc appointed Susan G. Kozauer, M.D., as Chief Medical Officer effective September 14, 2026. Dr. Kozauer brings over two decades of neuropsychiatric drug development experience, previously serving as Senior Vice President and Head of Clinical Development at Centessa Pharmaceuticals and Vice President in Clinical Development at Intra-Cellular Therapies. Her compensation includes a $515,000 annual base salary, a target bonus equal to 40% of her base, and a $150,000 one-time sign-on bonus payable over two years subject to continued employment. She will receive an option to purchase 200,000 shares of common stock vesting over four years as an inducement grant under Nasdaq Listing Rule 5635(c)(4). The company is a neuromedicines firm developing therapies for underserved brain disorders.
